Something happened this week that I genuinely didn't think I'd see.

A name that's been causing confusion, delayed diagnoses, and dangerously narrow treatment plans for decades has officially been retired. As of 12th May 2026, published in The Lancet — one of the most respected medical journals on the planet — Polycystic Ovary Syndrome is no longer.

It's now PMOS. Polyendocrine Metabolic Ovarian Syndrome.

One letter swapped. Enormous implications.

If you have PCOS — or think you might — keep reading. Because this isn't just a bureaucratic name change. It's the medical establishment finally catching up with what the research has been saying for years. And what many of us with this condition have been saying, full stop.

PMOS (Polyendocrine Metabolic Ovarian Syndrome) is the new official name for the condition previously known as PCOS, reflecting that it's a whole-body hormonal and metabolic condition — not just an ovarian issue.

The name change was published in The Lancet on 12th May 2026, following 14 years of global collaboration. It involved 56 patient and professional organisations across six continents, and drew on responses from over 22,000 patients and healthcare professionals worldwide. This wasn't a name change made in a meeting room. It was the result of one of the most rigorous, patient-centred naming processes in modern medical history.

The old name — Polycystic Ovary Syndrome — had a problem baked right into it. The word cystic implied pathological ovarian cysts. Except here's the thing: those aren't actually cysts. They're immature follicles. And a significant number of people diagnosed with PCOS don't have them at all. The name was, and has always been, medically inaccurate — and that inaccuracy had consequences.

The term PCOS led to missed diagnoses, fragmented care, and a dangerously narrow focus on fertility, while ignoring the metabolic, cardiovascular, and mental health implications of the condition.

Think about what happens when a condition is named after one feature — a feature that many patients don't even have. Every conversation, every Google search, every GP appointment gets filtered through that lens. Ovaries. Cysts. Fertility.

And everything else — insulin resistance, metabolic dysfunction, cardiovascular risk, mental health, skin, sleep, mood — gets treated as a side note. An afterthought. Something you might stumble across if you happen to go deep enough down a research rabbit hole at midnight.

Which is, frankly, exactly what most of us did.

"You're not imagining it." The old name really did narrow the conversation before it even started.

The harm of this isn't abstract. According to the Endocrine Society, the name PCOS contributed directly to:

• Delayed diagnoses — because without the classic presentation of cysts and fertility issues, many women weren't diagnosed at all
• Fragmented care — each specialist treating their slice of the condition (gynaecologist for periods, dermatologist for acne, GP for weight) without anyone joining the dots
• Missed metabolic investigation — particularly around insulin resistance and cardiometabolic risk, which are central to the condition
• Stigma — the focus on ovaries and fertility created shame and silence around a condition that affects 1 in 8 women worldwide

That's not a naming quirk. That's a systemic failure with real impact on real women's lives.

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome — each word reflects a different system the condition affects: hormones (polyendocrine), metabolism, and the ovaries.

Let's break it down, because the new name is doing a lot of heavy lifting.

Poly-endocrine — "Poly" means many. "Endocrine" refers to the hormonal system. This acknowledges that PMOS involves multiple hormonal disruptions — not just reproductive hormones, but insulin, cortisol, testosterone, and more. It's a hormonal condition, full stop.

Metabolic — This is the word that matters most. It signals directly that insulin resistance, blood sugar regulation, weight, cardiovascular health, and long-term metabolic risk are core to this condition — not optional extras. This is what many of us with PCOS have been saying for years. The science has agreed for years. The name just needed to catch up.

Ovarian — Retained deliberately. Not because the condition lives in the ovaries, but because the ovaries are meaningfully involved — in follicle development, hormone production, and reproductive function. The researchers considered using "reproductive" instead, but felt it was too stigmatising, particularly across different cultures and world regions.

Together, the name finally describes what this condition actually is: a complex, multi-system condition involving the endocrine system, metabolism, and ovarian function. A whole-body problem with a whole-body name.

In PMOS, metabolic dysfunction — primarily insulin resistance — shows up as everyday symptoms that are rarely connected to hormonal health: energy crashes, persistent hunger, weight that won't shift, brain fog, and mood instability.

This is the part that gets lost in clinical language. "Metabolic" sounds like something that lives in a blood test. But for most people with this condition, it lives in their body every single day — they just weren't told to connect the dots.

Here's what insulin resistance actually looks like in practice:

The 3pm energy collapse. Not ordinary tiredness. A wall. Your blood sugar spikes after a meal, your body floods the system with insulin to compensate, and you crash hard. Many women with PMOS spend years thinking this is normal, or a sign they need more coffee, or evidence they're just not coping well. It's none of those things. It's a metabolic signal.

Hunger that doesn't match how much you've eaten. When insulin isn't working efficiently, the message that you're full and fuelled doesn't reach your brain clearly. You can eat a full meal and feel hungry again within the hour. This isn't a willpower problem. It's a signalling problem — and the distinction matters enormously, both medically and emotionally.

Weight that doesn't respond to standard advice. Eat less, move more. It's the advice almost every woman with PCOS has received and almost every woman with PCOS has found doesn't work the way it's supposed to. That's because when insulin is chronically elevated, your body prioritises fat storage. Calorie restriction alone doesn't fix a hormonal signalling problem.

Brain fog. The kind where you walk into a room and forget why, or lose your train of thought mid-sentence, or feel like you're thinking through static. Glucose is the brain's primary fuel source. When blood sugar regulation is disrupted, cognitive clarity often goes with it.

Mood instability that tracks with eating. Anxiety, irritability, or low mood that arrives predictably after meals, or when you've gone too long without eating — this is blood sugar dysregulation showing up in your nervous system.

The research on this is actually pretty clear: these aren't separate problems that happen to coexist with a reproductive condition. They're downstream effects of the same metabolic disruption that also affects your cycle, your ovulation, your skin, and your androgen levels.

Hormonal literacy isn't complicated — it's just rarely taught. But when you understand that insulin is a hormonal driver of most of what you're experiencing, the whole picture starts to make sense.

The PMOS name change signals that metabolic investigation — including insulin resistance and cardiometabolic screening — should now be part of the standard diagnostic conversation from day one.

This is where the shift gets practical.

Under the old framework, PCOS was primarily a gynaecological diagnosis. You went to your GP. You mentioned irregular periods, maybe acne or hair loss. You might have had an ultrasound. You were handed the pill or told to lose weight and sent away.

What was rarely included in that appointment? A conversation about fasting insulin. About cardiometabolic risk. About how insulin resistance might be driving every single symptom you walked in with. About long-term risk of type 2 diabetes, cardiovascular disease, or the connection between your metabolism and your mental health.

The research on this is actually pretty clear — and has been for some time. Insulin resistance is present in an estimated 50–70% of people with PCOS, regardless of body weight. It drives androgen production. It disrupts ovulation. It affects mood, energy, skin, and sleep. It is central to the condition for the majority of people who have it.

And yet, most women find out about it the same way I did: alone, on the internet, years after diagnosis.

PMOS changes that — at least on paper. When the word metabolic is baked into the name of the condition itself, metabolic investigation becomes part of the diagnostic language. It's no longer optional. It's definitional.

There is a three-year transition period before PMOS is fully adopted in clinical practice, with updated international guidelines expected by 2028. So don't panic if your GP still says PCOS at your next appointment — they're not behind, they're just mid-transition. But you can use the new language now. And knowing what it represents gives you something powerful: a roadmap for what to ask for.

The PMOS renaming should lead to more joined-up care — addressing insulin resistance, mental health, skin, and cardiovascular risk alongside reproductive concerns, rather than treating each in isolation.

The fragmented care model has been one of the most frustrating parts of having this condition. You're a gynaecological patient here, a dermatological patient there, a mental health patient somewhere else. Nobody reads the whole file. Nobody asks about the metabolic picture.

With PMOS, the expectation shifts. A condition described as polyendocrine metabolic demands a multi-system response. That means:

• Insulin resistance should be investigated early — not only when diabetes risk becomes obvious
• Cardiovascular screening should be routine — because this is a cardiometabolic condition, and long-term heart health is part of the picture
• Mental health support should be integrated — the link between hormonal dysregulation and anxiety, depression, and mood instability is well-documented and should be part of the conversation
• Skin and hair presentations should be connected back to androgen and insulin pathways — not just treated topically
• Treatment should address root cause, not just visible symptoms

Root cause, not symptom suppression. That's been the MyOva position since day one. It's now the official scientific position too.

What joined-up PMOS care should actually look like in practice is worth spelling out — because knowing the benchmark is the first step to asking for it.

Metabolic investigation at diagnosis — not just an ultrasound and a hormone panel, but fasting insulin, fasting glucose, HbA1c, and a lipid panel. These give a picture of how your metabolism is actually functioning, not just whether your cycle fits a diagnostic checklist.

Androgen investigation in context — elevated testosterone or DHEAS isn't just a cosmetic problem causing acne and hair growth. In a PMOS framework, it's a metabolic signal. Androgens rise when insulin is high, because insulin stimulates androgen production in the ovaries. Treating the acne with a topical cream without addressing the insulin picture is symptom suppression, not treatment.

Long-term cardiometabolic monitoring — people with PMOS have a significantly elevated risk of type 2 diabetes and cardiovascular disease compared to the general population. This should be monitored regularly, not raised for the first time at a midlife health check.

Psychological support as standard — the link between PMOS and anxiety, depression, and disordered eating is well-established. This isn't incidental. Hormonal dysregulation and chronic blood sugar instability have direct effects on mood and mental health. Psychological support shouldn't be an optional referral — it should be part of the care plan.

Armed with the PMOS framework, there are specific, evidence-based questions you can bring to your next appointment to ensure your metabolic health is being investigated — not just your reproductive symptoms.

Most women with PCOS have left a GP appointment feeling like they didn't ask the right questions — or didn't know what the right questions were. That changes now.

Here are the exact questions worth raising, and why each one matters:

"Can we test my fasting insulin?" This is the single most important question on this list. Fasting insulin is not included in standard blood panels in the UK, but you can request it. It gives a direct window into how efficiently your body is managing insulin — the central driver of PMOS for most people. Without it, you're missing half the picture.

"Can we look at my full cardiometabolic profile?" This includes fasting glucose, HbA1c (a three-month average of blood sugar), and a lipid panel (cholesterol and triglycerides). Together, these tell you whether your metabolic health is being actively monitored or passively assumed.

"What is driving my androgen levels — and are we addressing the root cause?" If you have elevated testosterone or DHEAS, it's reasonable to ask whether the treatment plan addresses the insulin pathway driving it — not just the cosmetic result.

"I understand PMOS is now classified as a metabolic condition. What are we doing to address the metabolic component of my care?" This is the big one. It's direct, it's accurate, and it's backed by the same Lancet paper your GP will shortly be updating their clinical practice around. You're not being difficult. You're being informed.

"What does my long-term monitoring plan look like for cardiovascular and diabetes risk?" PMOS significantly raises lifetime risk of both. This should be an active conversation from the point of diagnosis — not something that surfaces in your 40s.

You don't need to ask all of these in one appointment. But walking in knowing which questions to raise, and why, is one of the most practical things the PMOS renaming has given you. Your body is trying to tell you something. These questions help you make sure your doctor is listening.

Not immediately — PMOS will be phased in over three years, with updated clinical guidelines due in 2028. But the new name gives you powerful language to use in medical appointments today.

Here's what changes now, practically:

You can use the new name. PMOS is the scientifically accurate term. Using it in appointments signals that you're informed — and it subtly shifts the frame of the conversation toward metabolic investigation.

You can ask different questions. Instead of only asking about your cycle or ultrasound results, you can ask: "Can we look at my fasting insulin? My cardiometabolic markers? My testosterone levels in the context of my metabolic health?" The name gives you permission to ask the whole question.

You can push back on narrow treatment. If you're offered the pill as the only option, you now have the language — and the scientific backing — to say: "I understand this is a metabolic condition. What are we doing to address that root cause?"

You can stop letting the 'cyst' confusion define your care. Whether or not you have the classic polycystic appearance on an ultrasound is less relevant than it was. The condition is defined by its hormonal and metabolic profile — and that's exactly what PMOS reflects.

This is what I have been building MyOva around for the past decade. Understanding the root cause of your symptoms, not just managing what's visible. The science has always supported this approach. Now the name does too.

Nothing changes at MyOva — because nothing we've been doing was built around the old name.

MyOva has always been built around the metabolic reality of this condition. The role of inositol in insulin sensitivity. The connection between blood sugar and ovulation. The link between cortisol, inflammation, and hormonal disruption. The importance of supporting the whole system — not just one symptom at a time.

When I founded MyOva after my own experience with PCOS and recurrent miscarriage, I did so because the standard approach — pill, weight loss advice, come back when you want to conceive — wasn't good enough. I'd done the research. I'd found the evidence for myo-inositol and its role in insulin sensitivity and egg quality. I built what I needed because it didn't exist yet.

That foundation hasn't changed. What's changed is that the medical world has now officially confirmed the approach.

If you're currently supporting your PCOS through a metabolic lens — focusing on blood sugar stability, reducing insulin resistance, supporting hormonal function through targeted nutrition and supplementation — you're already working within the PMOS framework. You were just ahead of the official terminology.

When did PCOS get renamed to PMOS? The official renaming was published in The Lancet on 12th May 2026, following a 14-year global consensus process involving 56 organisations and over 22,000 patients and professionals.

What does PMOS stand for? PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. The name reflects that the condition involves multiple hormonal systems (polyendocrine), has a significant metabolic component, and affects ovarian function.

Will my doctor start using the name PMOS? There is a three-year transition period underway, with updated clinical guidelines expected by 2028. Your doctor may still use PCOS during this period — that's normal. The change is being phased in systematically across clinical practice internationally.

Does the name change mean I'll get different treatment? Not automatically — but it should, over time. The PMOS name signals that metabolic investigation (including insulin resistance and cardiometabolic screening) should be part of standard care from diagnosis. If your current care doesn't include this, you can ask for it now.

Does having PCOS / PMOS mean I have cysts on my ovaries? No. Research published alongside the renaming confirmed there is no increase in abnormal ovarian cysts associated with the condition. The cysts referenced in the old name were always immature follicles — not true cysts. This was one of the primary drivers of the name change.

What is the metabolic component of PMOS? The metabolic element of PMOS refers primarily to insulin resistance and cardiometabolic risk. Insulin resistance is estimated to affect 50–70% of people with this condition regardless of body weight, and plays a central role in driving many of the hormonal disruptions associated with PMOS — including irregular ovulation, elevated androgens, weight changes, and mood instability.

This is the moment the medical world stopped pretending PCOS was just about ovaries.

It took 14 years. It took 56 organisations. It took 22,000 voices from patients and professionals across six continents. But the name has changed — and with it, the framework for how this condition should be understood, diagnosed, and treated.

PMOS: Polyendocrine Metabolic Ovarian Syndrome.

Every word matters. Every word is doing real work.

This is what I wish someone had told me years ago — that my hormones, my metabolism, my mood, my skin, my sleep, and my cycle are not separate stories. They're one story. And it's a metabolic one.

Your diagnosis is a starting point, not a verdict. And now, finally, it comes with a name that actually describes what's happening in your body.

Ready to support your hormonal health from the root?

MyOva's range is built around the metabolic reality of this condition — the same science the medical world just officially confirmed. 

Shop the MyOva supplement range →